KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Treasury Shares (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Treasury Shares for 14 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 215.48% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 215.48% increase, with the full-year FY2025 number at $1.5 million, up 215.48% from a year prior.
  • Treasury Shares was $1.5 million for Q4 2025 at Halozyme Therapeutics, up from $482403.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $19.1 million in Q2 2024 to a low of $482403.0 in Q4 2024.
  • A 5-year average of $5.1 million and a median of $4.0 million in 2021 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: surged 1074.93% in 2021, then crashed 74.68% in 2023.
  • Halozyme Therapeutics' Treasury Shares stood at $3.9 million in 2021, then rose by 15.38% to $4.5 million in 2022, then plummeted by 74.68% to $1.1 million in 2023, then crashed by 57.66% to $482403.0 in 2024, then surged by 215.48% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Treasury Shares are $1.5 million (Q4 2025), $482403.0 (Q4 2024), and $19.1 million (Q2 2024).